ClinicalTrials.gg
RecruitingNCT02938611MRC-GardUpdated Oct 20, 2026

Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

An observational study in Renal Insufficiency, Chronic, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 4 sites in France. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 10 months later.
Updated Oct 20, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
3,375
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 238 studies in Renal Insufficiency, Chronic with a site in France — 55 open to participants now, 69 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.

Planned enrollment
6th of 73
3,375 · median 165
Started
2019
with 12 others
Observational
73 of 238
20 open now
Primary completion
2027-12
later than 32 of 68 live
Registered
99th of 238
by date

Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 6th largest by planned enrollment of the 73 observational ones that give a count, is one of 13 that started in 2019, is one of 73 observational ones, reaches primary completion later than 32 of the 68 other live ones, and was the 99th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

55 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Renal Insufficiency, Chronic with a site in France, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

03

Conditions studied

  • Renal Insufficiency, Chronic
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Persons with >= stage 4 chronic kidney disease and residing in the Gard department of France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • chronic kidney disease (stage >= 4)

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
3,375 participants (estimated)
Patient registry
No

Groups and cohorts

  • The study population

    Persons with stage \>=4 chronic kidney disease.

06

What researchers measure

Primary outcomes

  1. The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)

    Time frame: from baseline (day 0) to 12 months

  2. The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)

    Time frame: from baseline (day 0) to 12 months

Secondary outcomes

  1. The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists

    Time frame: from baseline (day 0) to 12 months

  2. For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared

    Time frame: from baseline (day 0) to 12 months

  3. The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist

    Time frame: from baseline (day 0) to 12 months

07

Study locations

1 of 4 sites recruiting
  • AIDER - Unité de Dialyse d'Alès
    Alès, 30100, France
    Recruiting
    • Anne Wuillai, MD · Principal investigator
    • Médérick Mohajer, MD · Sub investigator
    • Farid Bellahsene, MD · Sub investigator
  • AIDER - Unité de Dialyse de Nîmes, CHU Carémeau
    Nîmes, 30029, France
    Not yet recruiting
    • Laure Patrier, MD · Principal investigator
    • Emilie Pambrun, MD · Sub investigator
  • CHU de Nîmes - Hôpital Universitaire Carémeau
    Nîmes, 30029, France
    Not yet recruiting
    • Olivier Moranne, MD, PhD · Principal investigator
    • Pascal Reboul, MD · Sub investigator
    • Sylvain Cariou, MD · Sub investigator
    • Sophie Renaud, MD · Sub investigator
    • Louis Marie Vernier, MD · Sub investigator
    • Frédérique Vecina, MD · Sub investigator
  • Gardialyse
    Nîmes, 30900, France
    Not yet recruiting
    • Samir Boubenider, MD · Principal investigator
    • Philippe Rousseau, MD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2027, 107 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 107 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2016
First posted
Oct 19, 2016
StartActual
Jan 1, 2019
Primary completionEst.
Dec 2027was Dec 2025
CompletionEst.
Dec 2027was Dec 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 France)
  • AIDER - Unité de Dialyse de Nîmes, CHU Carémeau · Nîmes, France
  • CHU de Nîmes - Hôpital Universitaire Carémeau · Nîmes, France
Show 2 removed
  • AIDER - Unité de Dialyse de Nîmes, CHU Carémeau · Nîmes Cedex 09, France
  • CHU de Nîmes - Hôpital Universitaire Carémeau · Nîmes Cedex 09, France
Oct 20, 2026
Primary completion
Dec 2025→Dec 2027
Oct 20, 2026
Study completion
Dec 2025→Dec 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 France)
    • AIDER - Unité de Dialyse de Nîmes, CHU Carémeau · Nîmes, France
    • CHU de Nîmes - Hôpital Universitaire Carémeau · Nîmes, France
    Show 2 removed
    • AIDER - Unité de Dialyse de Nîmes, CHU Carémeau · Nîmes Cedex 09, France
    • CHU de Nîmes - Hôpital Universitaire Carémeau · Nîmes Cedex 09, France
    Primary completion Dec 2025→Dec 2027
    Study completion Dec 2025→Dec 2027
    + 4 other changes: index terms, verification date, criteria formatting and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02938611
Responsible party
Sponsor
First posted
Oct 19, 2016
Start date
Jan 1, 2019
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Olivier Moranne, MD, PhD
Contact
olivier.moranne@chu-nimes.fr
+33.(0)4.66.68.31.49
Olivier Moranne, MD, PhD
study director · Centre Hospitalier Universitaire de Nīmes

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion